<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (10 mg m-2, 12 hourly by subcutaneous injection) was used to treat four patients with <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, two of whom had failed standard induction chemotherapy, and two patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation </plain></SENT>
<SENT sid="1" pm="."><plain>Following treatment two patients entered complete remission (CR) and two patients had survivals of ten and 18 months in stable partial remission </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients have died, four of progressive or recurrent <z:hpo ids='HP_0001909'>leukemia</z:hpo>, one of a treatment-related <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo>, and one of <z:mp ids='MP_0008714'>lung carcinoma</z:mp> while in CR </plain></SENT>
<SENT sid="3" pm="."><plain>Our experience, and a review of the literature, suggest that in general low dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> is well tolerated, although <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> is common and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> can be a major problem </plain></SENT>
<SENT sid="4" pm="."><plain>This form of treatment appears to offer a useful alternative to intensive induction chemotherapy in those patients in whom such treatment is usually poorly tolerated, and has the advantage of being able to be given to an outpatient </plain></SENT>
</text></document>